A Multi-center, Open, Prospective, Phase II Study of Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection in Patients With Relapse and Refractory B-cell Chronic Lymphocytic Leukemia
Phase of Trial: Phase II
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Shanghai Zhangjiang Biotechnology
- 21 Nov 2016 Planned End Date changed from 1 Dec 2015 to 1 Jun 2018.
- 21 Nov 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.
- 19 Nov 2013 New trial record